Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group


Por: Pérez FF, Lavernia J, Aguiar-Bujanda D, Miramón J, Gumá J, Álvarez R, Gómez-Codina J, Arroyo FG, Llanos M, Marin M, Alfaro J, Quero C, Delgado M, Nogales E, Menarguez F, Martínez N, Torrente M, Royuela A, Abreu D and Provencio M

Publicada: 1 mar 2017 Ahead of Print: 17 sep 2016
Resumen:
We reviewed 55 patients diagnosed with primary breast lymphoma, stages IE and IIE, in 16 Spanish institutions. Of the 55 cases, 96.4% corresponded to non-Hodgkin lymphoma. Results of 5-year progression-free and overall survival were 73% and 76%, respectively. Current treatments achieve good control of the disease, with an overall survival of 5 years in 80% of the patients. Introduction: Primary breast lymphoma is a rare form of localized extranodal lymphoma, which affects the mammary glands unilaterally or bilaterally, and can also affect the regional lymph nodes. Materials and Methods: We reviewed 55 patients, with disease stages IE and IIE, diagnosed in 16 Spanish institutions between 1989 and 2016. A serial of clinical variables and treatment were collected, and overall survival (OS) and progression-free survival (PFS) were calculated. Results: Of the 55 patients, 96.4% were women with an average age of 69 years. A total of 53 patients corresponded to non-Hodgkin lymphoma (NHL), of whom 36.3% had lymph node involvement upon diagnosis. Of the patients, 58.2% were stage IE, and 41.8% were stage IIE. Treatments received included radiotherapy (36.3%), chemotherapy (85.5%), and rituximab (in 38 of the 45 patients with NHL treated with chemotherapy). In all, 82.2% of complete responses were achieved. OS and progression-free survival at 5 years in NHL patients was 76% and 73%, respectively. Conclusion: Current treatments (chemotherapy, immunotherapy, and radiotherapy) achieve good control of the disease, with an OS of 5 years in 80% of the patients, although there is no consensus in treatment, given the scarce incidence of these lymphomas. (C) 2016 The Authors. Published by Elsevier Inc.

Filiaciones:
Pérez FF:
 Department of Medical Oncology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain.

Lavernia J:
 Department of Medical Oncology, Instituto Valenciano de Oncología, Valencia, Spain

Aguiar-Bujanda D:
 Department of Medical Oncology, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canarias, Spain

Miramón J:
 Department of Medical Oncology, Hospital Serranía de Ronda, Málaga, Spain

Gumá J:
 Department of Medical Oncology, Hospital Universitari Sant Joan de Reus, Reus, Spain

Álvarez R:
 Department of Medical Oncology, Hospital Universitario Virgen de la Salud, Toledo, Spain

Gómez-Codina J:
 Department of Medical Oncology, Hospital Universitari i Politècnic La Fe, Valencia, Spain

Arroyo FG:
 Department of Medical Oncology, Complejo Hospitalario de Pontevedra, Pontevedra, Spain

Llanos M:
 Department of Medical Oncology, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain

Marin M:
 Department of Medical Oncology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain

Alfaro J:
 Department of Medical Oncology, Instituto Oncológico de Kutxa, Donistia, Spain

Quero C:
 Department of Medical Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain

Delgado M:
 Department of Medical Oncology, Hospital Universitario San Cecilio, Granada, Spain

Nogales E:
 Department of Medical Oncology, Hospital Universitario Virgen de la Macarena, Sevilla, Spain

:
 Department of Medical Oncology, Hospital General Universitario de Elche, Alicante, Spain

Martínez N:
 Department of Medical Oncology, Hospital General Universitario de Elche, Alicante, Spain

Torrente M:
 Department of Medical Oncology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain

Royuela A:
 Department of Biostatistics, Hospital Universitario Puerta de Hierro, Majadahonda, Spain

Abreu D:
 Department of Medical Oncology, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canarias, Spain

Provencio M:
 Department of Medical Oncology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain
ISSN: 21522650





CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Editorial
CIG MEDIA GROUP, LP, 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 17 Número: 3
Páginas: 186-191
WOS Id: 000397459400008
ID de PubMed: 27847267

MÉTRICAS